Login to Your Account

Juno Therapeutics Inc., of Seattle, priced its eagerly awaited initial public offering (IPO) of about 11 million shares of common stock at $24 each, generating $264 million – making it the largest U.S. biotech IPO in the last 15 years.

A little more than five months after netting $95.6 million in its first follow-on offering, Bluebird Bio Inc. is leveraging its soaring share value (NASDAQ:BLUE) for a secondary offering, planning to raise $211.4 million through the sale of about 2.7 million shares priced at $85 each.

DUBLIN – Buoyed by six initial public offerings and two trade sales from its fourth fund, Versant Ventures formally closed its fifth fund, Versant Venture Capital V LP, at $305 million, $55 million ahead of target, with a mission to focus on early and late-stage biotechnology opportunities on either side of the Atlantic.

More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: